The ACR commends the FDA's proposal to require distinctive titles for biosimilar drugs and first biologics, stated Douglas White, MD, Chair of the ACR's Committee on Rheumatologic Treatment. Distinctive names permits higher transparency in substitution and notification, making it clear to all ongoing celebrations involved – pharmacists, providers and patients – which drug the patient is receiving. Related StoriesNo progression in joint damage in 84 percent of psoriatic arthritis patientsHSS experts help identify lupus individuals at increased threat of problem pregnanciesResistance strength training reduces pain, raises function in people with hand OAThe ACR previously issued a position statement calling on the FDA to enforce unique names for biosimilars, and provides spoken with FDA officials and submitted comment letters expressing its issues for patient basic safety in instances where biosimilars are substituted without appropriate patient and physician notification.Michigan Democrat Bart Stupak, who advanced the House-passed amendment, said the Senate abortion language is ‘not suitable. This content is definitely republished with kind permission from our friends at The Kaiser Family members Foundation. You will see the complete Kaiser Daily Health Plan Report, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, debates and discussions. The Daily Health Policy Report is released for Kaisernetwork.org, a free of charge services of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Age-specific management of asthma in children Adjustments to the National Asthma Council Australia asthma recommendations in the recently released Australian Asthma Handbook include age-specific recommendations on diagnosis, assessment and administration of asthma in kids.